•
Dec 31, 2023

Exact Sciences Q4 2023 Earnings Report

Generated record revenue and positive free cash flow.

Key Takeaways

Exact Sciences Corp. reported a revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023. The company also generated positive free cash flow during the quarter.

Total fourth quarter revenue was $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million

Total 2023 revenue was $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of $1.865 billion and Precision Oncology revenue of $629 million

Fourth quarter cash provided by operating activities was $70 million and free cash flow was $35 million

The company anticipates revenue of $2.810-$2.850 billion during 2024

Total Revenue
$647M
Previous year: $553M
+17.0%
EPS
-$0.27
Previous year: -$0.72
-62.5%
Gross Margin
70%
Previous year: 70%
+0.0%
Non-GAAP Gross Margin
73%
Previous year: 73%
+0.0%
Adjusted EBITDA
$49.7M
Previous year: $4.93M
+907.4%
Gross Profit
$454M
Previous year: $385M
+17.9%
Cash and Equivalents
$605M
Previous year: $242M
+149.6%
Free Cash Flow
$34.6M
Previous year: -$20.8M
-266.2%
Total Assets
$6.47B
Previous year: $6.23B
+3.9%

Exact Sciences

Exact Sciences

Exact Sciences Revenue by Segment

Forward Guidance

The company anticipates revenue of $2.810-$2.850 billion during 2024.

Positive Outlook

  • Screening revenue of $2.155-$2.175 billion
  • Precision Oncology revenue of $655-$675 million

Revenue & Expenses

Visualization of income flow from segment revenue to net income